A 1 receptor-mediated antiadrenergic effects are modulated by A 2a receptor activation in rat heart. Am. J. Physiol. 276 (Heart Circ. Physiol. 45): H341-H349, 1999.-Presently, the physiological significance of myocardial adenosine A 2a receptor stimulation is unclear. In this study, the influence of adenosine A 2a receptor activation on A 1 receptor-mediated antiadrenergic actions was studied using constant-flow perfused rat hearts and isolated rat ventricular myocytes. In isolated perfused hearts, the selective A 2a receptor antagonists 8-(3-chlorostyryl)caffeine (CSC) and 4-(2-[7-amino-2-(2-furyl) [1, 2, 4] triazolo [2,3-a][1,3,5]-triazin-5-ylamino]ethyl)phenol (ZM-241385) potentiated adenosine-mediated decreases in isoproterenol (Iso; 10 Ϫ8 M)-elicited contractile responses (ϩdP/dt max ) in a dose-dependent manner. The effect of ZM-241385 on adenosine-induced antiadrenergic actions was abolished by the selective A 1 receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (10 Ϫ7 M), but not the selective A 3 receptor antagonist 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(Ϯ)-dihydropyridine-3,5-dicarboxylate (MRS-1191, 10 Ϫ7 M). The A 2a receptor agonist carboxyethylphenethyl-aminoethyl-carboxyamidoadenosine (CGS-21680) at 10 Ϫ5 M attenuated the antiadrenergic effect of the selective A 1 receptor agonist 2-chloro-N 6 -cyclopentyladenosine (CCPA), whereas CSC did not influence the antiadrenergic action of this agonist. In isolated ventricular myocytes, CSC potentiated the inhibitory action of adenosine on Iso (2 ϫ 10 Ϫ7 M)-elicited increases in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) transients but did not influence Iso-induced changes in [Ca 2ϩ ] i transients in the absence of exogenous adenosine. These results indicate that adenosine A 2a receptor antagonists enhance A 1 -receptor-induced antiadrenergic responses and that A 2a receptor agonists attenuate (albeit to a modest degree) the antiadrenergic actions of A 1 receptor activation. In conclusion, the data in this study support the notion that an important physiological role of A 2a receptors in the normal mammalian myocardium is to reduce A 1 receptor-mediated antiadrenergic actions.
mediated through an inhibitory A 1 receptor subtype is readily discernible in isolated cell (6, 9) and whole heart preparations (4, 23) . In contrast to its inhibitory effects, adenosine via a stimulatory A 2 receptor subtype appears to increase myocardial contractility. Positive inotropic effects have been shown in ventricular muscle (1, 3, 17) and in isolated myocyte preparations (6, 13, 18, 26, 27) .
Despite escalating evidence in favor of an A 2 receptormediated positive inotropic action of adenosine, there is debate about the physiological significance of this effect. Adenosine A 2 receptor agonists have been reported to be without effect on both mechanical performance in cardiac myocytes (24) and in ventricular muscle preparations (2) as well as on cAMP concentrations in cardiac tissue (25) . In addition, in those studies where a positive inotropic influence of adenosine or its analogs was demonstrated in isolated myocyte preparations, either the A 1 receptor had been uncoupled from its effector (18, 26, 27) or A 2 receptor-induced effects were more readily apparent in the presence of an A 1 receptor antagonist (6) . These latter approaches employed to unmask the actions of A 2 receptor-mediated effects cast doubt on an independent physiological role of this receptor in a cardiac preparation with intact A 1 receptors.
The unmasking of A 2 receptor-mediated inotropic actions in isolated cell preparations subsequent to an intervention that reduces A 1 receptor or postreceptor cellular activity suggests that a significant interaction occurs between A 1 and A 2 receptor-induced effects. This, in turn, points toward an important modulating role of the A 2 receptor on A 1 receptor-mediated cardiac actions. Indeed, recent evidence showing an ability of an A 2a receptor antagonist to enhance A 1 receptor-induced antiadrenergic effects on mechanical performance in isolated ventricular myocytes, possibly through changes in Ca 2ϩ uptake (19) , supports this hypothesis.
The aim of this study was to investigate whether A 2a receptor-mediated effects have an important moderating influence on the antiadrenergic actions of adenosine in isolated perfused rat hearts and rat ventricular myocytes. In addition, this study evaluated whether these A 2a receptor-induced effects are in part explained by alterations in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ). The results indicate that A 2a receptor activation occurs simultaneously with A 1 receptor activation and subsequently produces an inhibitory influence on adenosine-induced antiadrenergic effects in both whole heart and cellular preparations.
METHODS
The animals used in this study were maintained and used in accordance with recommendations in the Guide for the Care 
Isolated Perfused Heart Preparation
Sixteen-week-old male Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN), weighing 380-540 g, were anesthetized with an intraperitoneal injection of ketamine (75 mg/kg) and xylazine (15 mg/kg). The hearts were then excised and immediately rinsed in ice-cold physiological saline solution (PSS). Hearts were perfused via the aorta at a constant flow with 37°C PSS containing (in mM) 118 NaCl, 4.7 KCl, 2.5 CaCl 2 , 25 NaHCO 3 , 1.2 KH 2 PO 4 , 1.2 MgSO 4 , and 10 glucose, at a pH of 7.40 gassed with 95% O 2 -5% CO 2 . The coronary flow rate was determined volumetrically and adjusted to achieve a flow of 10 ml · min Ϫ1 · g heart wt Ϫ1 , according to the approximate weight of the heart measured immediately before initiation of heart perfusion. The coronary perfusion pressure (CPP) was monitored from a sidearm of the aortic perfusion cannula with a Statham P23 transducer. Developed left ventricular (LV) pressure was determined using a water-filled, latex balloon-tipped cannula inserted via the left atrium into the LV cavity. The hearts were paced at 300 beats/min with the voltage 10% above threshold, via platinum wire electrodes attached to the left atrium and the apex of the heart. LV pressure and CPP were recorded using a polygraph (model RS 3400, Gould Instrument recorder). The maximum rates of LV pressure development (ϩdP/dt) and relaxation (ϪdP/dt) were obtained using a differentiator (model 13-4616-71, Gould Instrument Systems, Valley View, OH) with a high-frequency cutoff set at 300 Hz. Coronary flow per gram of ventricular heart weight was calculated at the end of each experiment.
Ventricular Myocyte Isolation
Isolated adult rat ventricular myocytes were prepared according to methods previously described (21) with several modifications. Sprague-Dawley rats were decapitated, and the hearts were excised and perfused at a constant pressure of 70 cmH 2 O for 10 min through the aorta with a filtered (0.45-µm membrane filter) perfusing solution (PS; pH 7.4, 37°C). The PS contained (in mM) 118 NaCl, 10 glucose, 25 NaHCO 3 , 4.69 KCl, 1.18 MgSO 4 , 1.18 KH 2 PO 4 , and 1.0 CaCl 2 . After equilibration, the hearts were constant-pressure perfused with PS containing no added Ca 2ϩ until spontaneous contractions ceased. The hearts were then perfused for 4-10 min with PS containing 0.48 mg/ml collagenase, 0.187 mg/ml hyaluronidase, 1.67 mg/ml recrystallized BSA, and 48.4 µM Ca 2ϩ at a rate of 3-4 ml/min for each heart. Ventricles were removed from the perfusion system, cut into pieces, and incubated with 5 ml of PS containing 0.72 mg/ml collagenase, 0.28 mg/ml hyaluronidase, 2.5 mg/ml BSA, and 50 µM Ca 2ϩ in a reciprocating water bath (40 cycles/min) with continuous gassing (95% O 2 -5% CO 2 ) for 7 min at 37°C. This procedure was repeated with fresh incubation solution three to five times. After the final incubation period, the solution was replaced with 10 ml of fresh incubation solution and shaken at 120 cycles/min for 12 min with gassing to dissociate the myocytes. The solution was filtered through a 250-µm nylon mesh into a 50-ml polypropylene tube to which 40 ml of PS containing 5 mg/ml BSA and 100 µM Ca 2ϩ (wash solution) were gradually added.
The myocytes were allowed to settle for 15 min, the upper two-thirds were aspirated, and 30-50 ml of fresh wash solution were added. After the myocytes were allowed to settle for a further 15 min, the wash solution was aspirated, and the myocyte pellet was resuspended in 30-50 ml MEM containing 200 µM Ca 2ϩ . After 15 min of settling, the modified MEM solution was aspirated, and the myocyte pellet was resuspended in MEM containing 500 µM Ca 2ϩ (ϳ10 ml). A 2-ml volume of the myocyte suspension was seeded onto each of five 60-mm culture dishes. These myocytes were incubated (37°C) and gassed (5% CO 2 in room air) for 1-3 h before use.
Fura 2 Fluorescence Measurements of [Ca 2ϩ ] i
Aliquots of ventricular myocytes were transferred to a 0.8-ml superfusion chamber that was mounted on the stage of a Nikon inverted microscope (Diaphot 300), and the cells were viewed using ϫ40 oil-immersion fluorescence objective lens (Nikon Fluor 40). The temperature was maintained at 37°C using a heated microscope stage plate (Fryer A-50 temperature controller). The myocytes were incubated with 6.25 µM fura 2-AM added to the modified PS. After 20 min, the cells were then superfused with PS-HEPES (PS modified by adding and changing the following: 1 mM glucose, 0.3 mM KCl, 0.25 mM CaCl 2 , and 10 mM HEPES, pH 7.4) for 15 min. Myocytes that were rod shaped, clearly striated, and mechanically quiescent, but responsive to electrical stimulation with a vigorous and reversible contraction, were selected for Ca 2ϩ transient measurements. Electrical stimulation (model SD9, Grass Instruments, Quincy, MA) at 0.5 Hz was provided by platinum wire electrodes attached to the bottom of the chamber. After a myocyte was selected, all but the myocyte was blocked from the field of view, thereby minimizing background fluorescence. Because the autofluorescence of the myocytes was negligible (ϳ1% of the individual 340-and 380-nm signals), there was no need to subtract this from the recorded signals. Fluorescent dye internalized within the cell was excited by incident light, provided by a high-speed dual-wavelength scanning illuminator (xenon arc lamp, 75 W) capable of switching between excitation light of 340 and 380 nm at a speed of 650 ratios/s (Delta Scan, Photon Technology International, Brunswick, NJ). Light emitted by the cells was detected at 520 nm by a photomultiplier tube and recorded at 50 points/s using a computer-based data acquisition system (Felix, Fluorescence Analysis Software, Photon Technology International). In vivo calibrations were performed at the end of the experiment by exposure of the myocyte, in the presence of Triton X-100, to CaCl 2 followed by EGTA in the absence of Ca 2ϩ , to determine maximum ratio (R max ) and minimum ratio (R min ). [Ca 2ϩ ] i was calculated according to the following formula: [Ca 2ϩ (9, 14) , using an estimated dissociation constant (K d ) of 200 nM and ␤, the ratio of permeabilized myocyte 380-nm fluorescence in the presence of EGTA to the 380-nm fluorescence in the presence of the maximum concentration of CaCl 2 .
Protocol for Isolated Hearts
Agents were infused just proximal to the aortic cannula at rates Ͻ3% of the perfusion rate to achieve the desired concentration in the perfusate. For each protocol, the preparation was allowed to stabilize for at least 15 min before eliciting baseline adrenergic responses. Adrenergic responses were induced every 5 min by 20-s infusions of isoproterenol (Iso) to achieve an Iso concentration of 10 Ϫ8 M in the PSS. The (16, 20) , on Iso-elicited contractile responses was assessed in the presence and absence of adenosine. First, experiments were conducted with a series of progressively increasing concentrations of adenosine A 2 receptor antagonists in the presence of either 10 Ϫ6 M adenosine or the adenosine vehicle (0.9% NaCl). Iso challenges were repeated at the end of each 5-min infusion of either CSC (ranging from 10 Ϫ8 to 10 Ϫ6 M) or ZM-241385 (ranging from 10 Ϫ9 to 10 Ϫ6 M). This protocol was employed to determine the concentration range of CSC or ZM-241385 over which adenosine-induced antiadrenergic effects may be influenced by adenosine A 2a receptor activity.
Second, the inhibitory effect of adenosine on adrenergic responses was ascertained in the presence of a continuous infusion of 10 Ϫ6 M CSC, 10 Ϫ6 M ZM-241385, or the vehicle of these agents. Iso challenges were repeated at the end of each 5-min infusion of progressively increasing concentrations of adenosine ranging from 10 Ϫ8 to 10 Ϫ4 M. An adenosine concentration inhibition curve was determined in the presence of a continuous infusion of either the vehicle of CSC or ZM-241385, (10 Ϫ6 M CSC or 10 Ϫ6 M ZM-241385). The above time periods of either adenosine or A 2a antagonist infusion were established as producing either no effects or minimal effects on CPP. Longer periods of infusion resulted in alterations in CPP that would have obscured the interpretation of the changes in cardiac mechanical performance noted subsequent to A 2a receptor antagonist administration. Finally, the effect of incremental concentrations of DMSO, the vehicle of CSC and ZM-241385, on Iso-mediated responses in the absence or presence of 10 Ϫ6 M adenosine was also assessed.
Group B. To exclude whether CSC, independent of A 2a receptor inhibition, modulates A 1 receptor-induced antiadrenergic effects, the A 1 receptor selective agonist 2-chloro-N 6 -cyclopentyladenosine (CCPA) was infused either with CSC (10 Ϫ6 M) or with the vehicle for CSC. To determine the CCPA dose-response relationship, Iso challenges were repeated at the end of a 5-min infusion of each incremental concentration of CCPA ranging from 10 Ϫ9 to 10 Ϫ5 M.
Group C. To examine whether A 2a receptor inhibition modulates adenosine-induced antiadrenergic effects by potentiating A 1 and/or A 3 receptor actions, either the selective A 1 receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX; 10 Ϫ7 M) or the selective A 3 receptor antagonist 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(Ϯ)-3,5-dicarboxylate (MRS-1191, 10 Ϫ7 M) (15) was infused with adenosine (10 Ϫ6 M) and ZM-241385 (10 Ϫ6 M). Iso challenges were repeated before and at the end of each 5-min sequential infusion of adenosine alone, adenosine with ZM-241385, and then either adenosine with both ZM-241385 and DPCPX, or adenosine with both ZM-241385 and MRS-1191. Separate groups of rat hearts were used to examine the influence of either DPCPX or MRS-1191 on the effect of ZM-241385 on the antiadrenergic action of adenosine.
Group D. To further evaluate whether modulation of adrenergic responses can be attributed, in part, to an interaction that occurs between A 2a and A 3 receptors, the effect of the selective A 3 receptor agonist 4-aminobenzyl-5-N-methylcarboxyamidoadenosine (AB-MECA; 10 Ϫ6 M) (12) on Iso-elicited contractile responses was assessed in both the presence and the absence of ZM-241385 (10 Ϫ6 M).
Group E. To examine whether A 1 receptor-induced antiadrenergic effects could be modified by the simultaneous activation of A 2 receptors, the A 2 -selective agonist carboxyethylphenethyl-aminoethyl-carboxyamido-adenosine (CGS-21680) was infused with or without CCPA. The antiadrenergic actions of CCPA were evaluated using Iso challenges repeated at the end of each 5-min infusion of incremental concentrations of CCPA ranging from 10 Ϫ9 to 10 Ϫ5 M. A CCPA concentration inhibition curve was determined in the presence of a continuous infusion of either the vehicle of CGS-21680, 10 Ϫ6 M CGS-21680, or 10 Ϫ5 M CGS-21680. The effect of the simultaneous infusion of the vehicle of CCPA and CGS-21680 on adrenergic responsiveness was also examined.
Protocol for Isolated Ventricular Myocytes
To evaluate whether adrenergic-mediated increases in myocyte [Ca 2ϩ ] i transients are simultaneously modulated by A 1 and A 2 receptor activation, isolated myocytes were exposed to Iso as well as to Iso and adenosine with or without CSC. After myocyte [Ca 2ϩ ] i transients had stabilized, [Ca 2ϩ ] i transients were obtained with myocytes exposed to a continuous infusion of 2 ϫ 10 Ϫ7 M Iso in the presence of the vehicles of CSC and adenosine. The antiadrenergic effects of adenosine and the ability of CSC to modulate this response were then assessed by infusing either 10 Ϫ6 , 10 Ϫ5 , or 10 Ϫ4 M adenosine with Iso and, subsequently, adenosine together with CSC (10 Ϫ6 M) and Iso. Each adenosine concentration required separate myocyte preparations because the action of CSC on adenosine-induced antiadrenergic effects was difficult to reverse during the washout period. To determine whether CSC alters adrenergic responsiveness independent of adenosine, Iso responses were obtained in a separate group of cell preparations in the presence or absence of 10 Ϫ6 M CSC.
Statistical Analysis
The concentration of adenosine or CCPA that produced 50% of the maximal inhibitory response (IC 50 ) in isolated perfused hearts was determined from nonlinear regression analysis using sigmoid curve fitting. If the concentration of a ligand required to produce a maximal response could not be definitely determined, an apparent IC 50 was calculated.
Repeated measures ANOVA, followed by either a Dunnett's or a Student-Newman-Keuls test, were used to evaluate the effects of adenosine receptor agonist (adenosine, CCPA, CGS-21680, or AB-MECA) and antagonist (CSC, ZM-241385, DPCPX, or MRS-1191) ligands on either adrenergic or antiadrenergic responsiveness. An unpaired Student's t-test was used to compare IC 50 values between groups. A P value of Ͻ0.05 was taken to indicate a statistically significant difference. All data are expressed as means Ϯ SE.
Materials
Isoproterenol and adenosine were dissolved in 0.1% sodium metabisulfite or H 2 O, respectively. CSC, ZM-241385, MRS-1191, AB-MECA, CCPA, and CGS-21680 stock solutions were all dissolved in DMSO and diluted with water, such that the highest concentration of each substance used was associated with a 0.05% DMSO concentration in the perfusate.
Isoproterenol, HEPES, EGTA, BSA, Triton X-100, and DMSO were purchased from Sigma Chemical (St. Louis, MO). 
RESULTS

Isolated Perfused Hearts
A 2 receptor blockade potentiates the antiadrenergic effects of adenosine. The A 2a receptor antagonists CSC and ZM-241385 were found to decrease Iso-elicited contractile responses (ϩdP/dt max ) in the presence, but not in the absence, of adenosine. Incremental concentrations of both adenosine A 2a receptor antagonists enhanced the antiadrenergic effects of 10 Ϫ6 M adenosine in a dose-dependent manner (Fig. 1) . Adenosine (10 Ϫ6 M) suppressed the contractile response to Iso (ϩdP/ dt max ) by 11 Ϯ 4% in the absence of CSC and by 34 Ϯ 7% in the presence of 10 Ϫ6 M CSC infusion (P Ͻ 0.05).
Similarly, 10 Ϫ6 M adenosine attenuated the contractile response to Iso by 5 Ϯ 2% in the absence of ZM-241385 to 28 Ϯ 2% in the presence of 10 Ϫ6 M ZM-241385 (P Ͻ 0.05). The infusion of either CSC or ZM-241385 together with the vehicle of adenosine did not alter adrenergic responses to Iso despite significant increases in the baseline contractile state (CSC increased ϩdP/dt max from 1,531 Ϯ 77 to 1,922 Ϯ 243 mmHg/s; and ZM-241385 increased ϩdP/dt max from 1,500 Ϯ 103 to 2,328 Ϯ 217 mmHg/s). In addition, DMSO, the vehicle of CSC and ZM-241385, did not alter adrenergic responses in either the presence or absence of adenosine (data not shown). CSC at higher concentrations resulted in an increase in CPP in the group receiving adenosine (CPP with 10 Ϫ6 M adenosine alone ϭ 71 Ϯ 4 mmHg; CPP with adenosine and CSC ϭ 89 Ϯ 17 mmHg; P Ͻ 0.05). However, no significant changes in CPP occurred in response to ZM-241385 (data not shown).
Both A 2a receptor antagonists produced a leftward shift in the concentration-inhibition curve of adenosine (Fig. 2) . Reducing the influence of A 2 receptors with CSC and ZM-241385 unmasked the antiadrenergic http://ajpheart.physiology.org/ effect of adenosine at a concentration (10 Ϫ7 M) that under control conditions did not result in a significant attenuation of Iso-elicited responses (Fig. 2) . The IC 50 value for adenosine-induced antiadrenergic effects was decreased 8-fold after CSC (Fig. 2, top, inset) and 10-fold after ZM-241385 (Fig. 2, bottom, inset) administration. The differences in the IC 50 values after either CSC or ZM-241385 compared with those exposed to the vehicle of CSC and ZM-241385 (Fig. 2) could not be accounted for by differences between the groups in coronary flow (in ml · min Ϫ1 · g heart wt Ϫ1 ; vehicle of CSC ϭ 9.35 Ϯ 0.30, CSC ϭ 9.37 Ϯ 0.41; vehicle of ZM-241385 ϭ 10.35 Ϯ 0.45, ZM-241385 ϭ 11.0 Ϯ 0.28) or CPP. Finally, whereas CSC potentiated the antiadrenergic influence of adenosine, CSC did not alter the antiadrenergic effect of the selective A 1 receptor agonist CCPA (data not shown). The IC 50 values for CCPA remained unchanged after CSC administration (with CSC, 1.88 Ϯ 0.54 ϫ 10 Ϫ7 M; without CSC, 1.9 Ϯ 0.69 ϫ 10 Ϫ7 M). Thus A 2 receptor blockade did not potentiate the antiadrenergic effect of an agonist that selectively activates A 1 and not A 2 receptors.
A 1 receptor, but not A 3 receptor, antagonists abolished the potentiating effect of ZM-241385 on the antiadrenergic actions of adenosine.
The selective A 1 receptor antagonist DPCPX at 10 Ϫ7 M abolished the potentiating effect of the A 2a receptor antagonist ZM-241385 on adenosine-induced antiadrenergic actions (Fig. 3,  top) . However, the selective A 3 receptor antagonist MRS-1191 at 10 Ϫ7 M failed to attenuate the action of ZM-241385 on adenosine-induced antiadrenergic actions (Fig. 3, bottom) . In addition, the selective A 3 receptor agonist AB-MECA at 10 Ϫ6 M was unable to mediate antiadrenergic actions in either the presence or absence of the A 2a receptor antagonist ZM-241385 at 10 Ϫ6 M (data not shown). Infusion of the vehicles for the various agents did not alter Iso-elicited contractile responses.
Interaction between A 2 and A 1 receptors. The selective A 2 receptor agonist CGS-21680 at 10 Ϫ5 M (Fig. 4) , but not at 10 Ϫ6 M (data not shown), reduced the antiadrenergic actions of the higher concentrations of the selective A 1 receptor agonist CCPA. However, CGS-21680 (10 Ϫ5 or 10 Ϫ6 M) did not change the apparent IC 50 (M) for CCPA (CCPA ϩ CGS-21680 at 10 Ϫ5 M, 0.24 Ϯ 0.094 ϫ 10 Ϫ7 M; CCPA ϩ vehicle, 1.33 Ϯ 0.5 ϫ 10 Ϫ7 M). (Table 1) . Infusion of 2 ϫ 10 Ϫ7 M Iso resulted in a 90 Ϯ 22% increase in [Ca 2ϩ ] i transients. When 10 Ϫ5 M adenosine was administered with Iso, the [Ca 2ϩ ] i transients decreased significantly by 32 Ϯ 5% in the absence of CSC and by 58 Ϯ 8% in the presence of 10 Ϫ6 M CSC. CSC alone produced no effect on the Iso-induced increment in the amplitude of the myocyte [Ca 2ϩ ] i transients (Fig.  5, Table 1 ). Neither adenosine nor CSC produced significant effects on diastolic [Ca 2ϩ ] i (data not shown).
DISCUSSION
Adenosine A 2a receptors have been identified to coexist with A 1 receptors on the myocyte cell membranes (6, 18) . However, the functional role of myocardial A 2a receptors is as yet not fully understood. The principal finding of this study suggests that an important role of A 2a receptor activation is to counteract the antiadrenergic actions of adenosine. This effect appears to be attributable to an interaction between A 2a and A 1 , and not between A 2a and A 3 , receptors. The findings of this study further indicate that a potential mechanism by which A 2a receptor activation inhibits the antiadrenergic action of adenosine involves a reduction in ␤-adrenoceptor-mediated increases in cardiac myocyte [Ca 2ϩ ] i .
A 2a Receptor Blockade Enhances the Antiadrenergic Actions of Adenosine
The inhibitory effects of exogenous adenosine on Iso-elicited contractile responses were markedly potentiated after A 2a receptor blockade in intact rat hearts and in isolated rat cardiac myocytes. A xanthine with selective A 2a receptor antagonist properties, CSC (11), augmented the antiadrenergic actions of adenosine in the isolated perfused heart, but not that of the selective A 1 receptor agonist CCPA (11) . CSC further enhanced the adenosine-mediated decreases in Iso-elicited increments in isolated cardiac myocyte [Ca 2ϩ ] i . In addition, a nonxanthine with selective A 2a receptor antagonist properties, ZM-241385 (16, 20) , similarly potentiated the antiadrenergic actions of adenosine. This action of ZM-241385 was abolished by DPCPX, an A 1 receptor blocker (11) . Neither CSC nor ZM-241385 had a significant effect on Iso-elicited responses in the absence of adenosine. This suggests that these selective A 2a receptor antagonists enhanced the antiadrenergic actions of adenosine via A 2a receptor blockade rather than by a nonspecific antiadrenergic effect. In general, the data on the actions of A 2a receptor blockade are in agreement with prior work performed in myocyte shortening experi- (19) . These investigators demonstrated an enhanced antiadrenergic action of an adenosine analog following A 2a receptor blockade (19) .
An important difference between the present results and the data of Laing and Morley (19) is the degree to which A 2a receptor blockade accentuated A 1 receptormediated antiadrenergic actions. Although the aforementioned investigators did not provide results that allowed for a quantitative interpretation of their data, the representative results provided suggest that CSC produced only a modest effect on A 1 receptor-mediated antiadrenergic actions. In this study, A 2 receptor blockade was associated with a profound increase in A 1 receptor-mediated antiadrenergic effects. Possible explanations for the quantitative differences noted in this study and that of Liang and Morley (19) include, first, that the influence of CSC on adenosine-induced antiadrenergic actions was quantitatively characterized largely in intact hearts, rather than in isolated cardiac myocytes. Second, there are potential differences in the binding characteristics of the adenosine receptor agonist for the A 2a receptor used in this study compared with that used by Liang and Morley (19) . These investigators used an adenosine agonist R-phenylisopropyladenosine, with a lower potency at the A 2a receptor (11) in comparison with adenosine, the agonist used in this study. Third, in the current study, a protocol was employed that induced marked adrenergic responses in perfused hearts (ϳ225% increase in ϩdP/dt max ) in comparison with those produced by Liang and Morley (19) in isolated myocytes (ϳ37% increase in myocyte shortening). The former approach may have improved the ability to detect small but significant differences in adrenergic responses at relatively low concentrations of adenosine. Fourth, the A 1 -A 2a receptor interaction in this study was examined over a broad ligand concentration range, and the most profound effect of both CSC and ZM-241385 was noted over an intermediate range of adenosine concentrations. This approach was not adopted by Liang and Morley (19) , and it is possible that the investigators may not have used an ideal concentration of the adenosine analog to show the same degree of effect of CSC on A 1 receptor-induced antiadrenergic actions as observed in this study. Finally, species differences might explain the quantitative differences in the results.
Taken together, the data on A 2a receptor blockade suggest that if cardiac A 1 and A 2 receptors are simultaneously activated to modulate adrenergic responses, adenosine-mediated A 2a receptor activation induces effects that oppose the A 1 receptor-mediated antiadrenergic actions. Furthermore, the fact that myocardial A 2a receptor blockade was able to potentiate the action of intermediate to low concentrations of adenosine on adrenergic effects argues for its physiological importance. Infusion of either one of the A 2a receptor antagonists with 10 Ϫ7 M adenosine, a concentration that under control conditions did not produce a significant attenuation of Iso-elicited responses, resulted in a significant depression of adrenergic responses. The latter finding is consistent with the hypothesis that ventricular A 2a receptors mediate functional effects at adenosine concentrations that are considered to be physiological (7, 10, 17) . The other myocardial A 2 receptor subtype, the A 2b receptor, is thought to mediate physiological effects only at high adenosine concentrations (18) .
Interactive Cardiac Effects of A 2 and A 1 Receptor Agonists
The effects of an A 2 receptor agonist, CGS-21680, on the antiadrenergic actions of an A 1 receptor agonist, CCPA, were evaluated in isolated perfused hearts to further explore the extent of the interaction between A 2a and A 1 receptors. Although quantitatively a modest effect, CGS-21680 attenuated the antiadrenergic actions of the higher concentrations of CCPA, whereas CGS-21680 alone had no effect on Iso-elicited responses. However, the A 2 agonist did not alter the apparent IC 50 value for CCPA-mediated antiadrenergic effects. The lack of effect of CGS-21680 on the apparent IC 50 value for CCPA-mediated antiadrenergic effects may reflect an inability to use higher concentrations of CCPA. The dose-response relationship for CCPA alone illustrated in Fig. 4 is not a sigmoid relationship. To achieve a sigmoid fit to the latter curve, a higher concentration of CCPA was needed. However, higher concentrations of CCPA would have resulted in CCPA vehicle (DMSO)-mediated adverse effects on the heart. Finally, adenosine may mediate antiadrenergic effects via activation of both A 1 and A 3 receptors, whereas CCPA is expected to predominantly transduce antiadrenergic effects via the A 1 receptor. Thus it may be argued that unmasking the antiadrenergic effects of A 1 and A 3 receptor activation as a consequence of A 2 receptor blockade may result in greater augmentation of the antiadrenergic effects of adenosine than the inhibitory effects of the stimulatory action of the A 2 receptor agonist on antiadrenergic properties of the selective A 1 receptor agonist. There is reason to believe that this scenario is unlikely, since the potentiating effect of action of ZM-241385 on the antiadrenergic actions of adenosine was completely reversed by DPCPX, a selective A 1 receptor blocker (11), but not by MRS-1191, a selective A 3 receptor antagonist (15) . Furthermore, infusion of AB-MECA, a selective A 3 receptor agonist (12), did not result in altered adrenergic responses in either the presence or absence of an A 2a receptor antagonist.
CGS-21680 did not augment Iso-induced adrenergic responses. This differs from results obtained in isolated avian cardiac myocytes (19) . A possible reason for the discrepancy between these two lines of evidence is that the Iso concentration used in the present study produced a marked increase in contractility in comparison with that produced by the investigators who showed an additive effect of the action of CGS-21680 on adrenergic responses (19) . Hence, in the present study, the capacity to augment the already profound adrenergicmediated inotropic responses may have been limited. In support of a potentiating effect of A 2 receptor activation on ␤-adrenoceptor-mediated contractile responses, CGS-15943, an A 2 antagonist, attenuates Iso-elicited contractile responses in perfused hearts (22) , presumably by inhibiting the actions of endogenous adenosine. In the present study, a possible endogenous adenosinemediated effect on A 2 receptors was not examined.
Despite some reservations about the expected effects of CGS-21680 on the antiadrenergic effects of CCPA, the effects of this A 2 agonist at higher doses of CCPA support the hypothesis that a significant interaction occurs between A 1 and A 2a receptors in modifying adrenergic responses. Although CGS-21680 binds to A 2b receptors, its main action is on A 2a receptors (18) . Therefore, although a possible influence of CGS-21680 on A 2b receptors cannot be excluded, it is likely that the latter pharmacological agent attenuated A 1 receptorinduced antiadrenergic effects through A 2a receptor activation.
Isolated Myocyte [Ca 2ϩ ] i Transients
One mechanism by which A 2a receptor activation might attenuate A 1 receptor-induced antiadrenergic effects was explored. It has been suggested that A 2a receptors are coupled to G s , which mediate contractile responses through cAMP-dependent and -independent pathways (6, 19) , both of which may activate L-type Ca 2ϩ channels and subsequently increase [Ca 2ϩ ] i (19) . In support of a hypothesis that alterations in [Ca 2ϩ ] i , in part, mediate the potentiated antiadrenergic action of an A 1 receptor agonist by an A 2a receptor antagonist, CSC enhanced adenosine-mediated decreases in Isoelicited increments in [Ca 2ϩ ] i transients.
In conclusion, the present results indicate that A 2a receptor activation or inactivation modulates the antiadrenergic influence of A 1 receptor-mediated effects. Both xanthine and nonxanthine A 2a receptor antagonists potentiate the antiadrenergic actions of adenosine through an effect that is blocked by A 1 , but not A 3 receptor selective antagonists, whereas an A 2 receptor agonist attenuates (albeit to a modest degree) the antiadrenergic effects of an A 1 receptor agonist. In addition, the present results indicate that the augmented antiadrenergic action of adenosine on ␤-adrenoceptor-mediated contractile responses following A 2a receptor blockade is in part mediated through a decrease in [Ca 2ϩ ] i transients. These results suggest that although the predominant impact of adenosine on adrenergic responses is an A 1 receptor-mediated antiadrenergic action, a profound modulating influence of proadrenergic A 2a receptor-induced effects also occurs. The importance of the modulating influence of A 2a receptor-mediated actions in the ischemic, hypoxic, or failing myocardium (5), where interstitial levels of adenosine are elevated (8) , requires further investigation.
